Development and validation of a targeted gene sequencing panel for application to disparate cancers
Mark J. McCabe(Garvan Institute of Medical Research), Manisha Chauhan(Garvan Institute of Medical Research), Lesley Andrews(Prince of Wales Hospital), Kevin Ying(Garvan Institute of Medical Research), Leon Botes(Cancer Institute of New South Wales), Reginald V. Lord(University of Southern California), Maija R.J. Kohonen‐Corish(Garvan Institute of Medical Research), Morteza Aghmesheh(New South Wales Department of Health), Yoland Antill(Peninsula Health), Mélissa Thomas(Murdoch University), Ian Campbell(The University of Sydney), Matthew Burgess(Royal Hobart Hospital), Amber L. Johns(Garvan Institute of Medical Research), Alexander Swarbrick(Garvan Institute of Medical Research), John Beilby(Queen Elizabeth II Medical Centre), Clare Puttick(The Francis Crick Institute), Niantao Deng(Millennium Engineering and Integration (United States)), Ian Bennett(Wesley Hospital), Sandra O’Toole(The University of Sydney), Marcel E. Dinger(The University of Sydney), Tao Jiang(Chinese Academy of Medical Sciences & Peking Union Medical College), John P. Grady(Garvan Institute of Medical Research), Sunita M C De Sousa(South Australia Pathology), Jo Burke(Royal Prince Alfred Hospital), Michael Bogwitz(The Royal Melbourne Hospital), David F. Callen(Sarcoma Oncology Center), Velimir Gayevskiy(Rancho BioSciences (United States)), Patti Bastick(QIMR Berghofer Medical Research Institute), Mark J. Cowley(Garvan Institute of Medical Research), Leanne Arnold(Royal Brisbane and Women's Hospital), Arcadi Cipponi(The Kinghorn Cancer Centre), Ruta Gupta(Cedars-Sinai Medical Center), David J. Amor(The University of Melbourne), Rosemary L. Balleine(The University of Sydney), Shane Armitage(Royal Brisbane and Women's Hospital), Simon A. Mueller(University Hospital Zurich), Anneke C. Blackburn(Australian National University), Tanya Thompson(Garvan Institute of Medical Research), Jonathan Beesley(The University of Melbourne), Jonathan R. Clark(The University of Sydney), Ann McCormack(Garvan Institute of Medical Research), Melissa A. Brown(Wellcome Centre for Cell-Matrix Research), Michael F. Buckley(New South Wales Department of Health), Phyllis Butow(Garvan Institute of Medical Research), Chia-Ling Chan(Garvan Institute of Medical Research), Meagan Brennan(The University of Queensland), Deepa Chauhan(The University of Sydney), Liz Caldon(Garvan Institute of Medical Research)
Cited by 32
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility
|Nature Genetics|2014|1.1k
Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk
|PLoS ONE|2015|906
Long noncoding RNAs in mouse embryonic stem cell pluripotency and differentiation
|Genome Research|2008|742